Results 41 to 50 of about 16,301 (208)
Nutrition & Diabetes, 2023 Background Fenofibrate is a hypolipidemic peroxisome proliferator-activated receptor α (PPARα) agonist used clinically to reduce hypercholesterolemia and hypertriglyceridemia. Objective We investigated the effects of fenofibrate on insulin resistance and
Jungu Lee +3 more
doaj +1 more source
EBioMedicine, 2016 Neovascular eye diseases including retinopathy of prematurity, diabetic retinopathy and age-related-macular-degeneration are major causes of blindness.
Yan Gong +14 more
doaj +1 more source
Fenofibrate treatment for severe hypertriglyceridemia in dogs
, 2021 Lipid disorders are relatively common in dogs. Hyperlipidemia can be primary or secondary to other diseases. In humans, fenofibrate is used to control hypertriglyceridemia. In dogs, there are no studies evaluating fenofibrate in hypertriglyceridemia. The
Miceli, Diego Daniel +4 more
core +1 more source
Italian Journal of Animal Science, 2022 So far, the effect of fenofibrate on the performance, quantitative and qualitative characteristics of broilers have not been investigated. For this reason, this study was performed to evaluate the effects of different levels of fenofibrate on the ...
Maryam Azizi +2 more
doaj +1 more source
Scientific ReportsDiabetic corneal neuropathy (DCN) is a common diabetic ocular complication with limited treatment options. In this study, we investigated the effects of topical and oral fenofibrate, a peroxisome proliferator-activated receptor-α agonist, on the ...
Hassan Mansoor +10 more
doaj +1 more source
Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2. [PDF]
PLoS ONE, 2013 The orphan nuclear receptor, small heterodimer partner (SHP), appears to play a negative regulatory role in innate immune signaling. Emerging evidence warrants further study on the therapeutic targeting of SHP to suppress excessive and deleterious ...
Chul-Su Yang +8 more
doaj +1 more source
ChemSusChem, Volume 18, Issue 6, March 15, 2025.we have developed an electrochemical Ni−H catalyzed arylation coupling method of unactivated alkenes with aryl halides. The method displays broad functional group tolerance and proceeds under very mild conditions. Furthermore, aryl chlorides were also compatible substrates in this catalytic system. This conversion holds significant implications for the
Chao Xu, Ru‐Han A, Xiao‐Feng Wu
wiley +1 more source
Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs. [PDF]
PLoS ONE, 2015 Nephrotoxicity is a major side effect for the antineoplastic drug cisplatin. Here, we employed pharmacological, biochemical, and molecular studies to investigate the role of peroxisome proliferator-activated receptors (PPARs) in cisplatin nephrotoxicity.
Mai M Helmy +2 more
doaj +1 more source
Biomedical Sciences and Clinical Medicine, 2022 Fenofibrate, a lipid lowering drug, can increase the effects of warfarin and may cause bleeding more easily. We report a case of a 58-year-old Thai male patient who was administered warfarin at 27 mg per week to achieve the target international ...
Kanokwan Thitiratamornkit +2 more
doaj +1 more source
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Epilepsia Open, EarlyView.Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source